Charles Karan

This study identifies non-oncogene dependencies in imatinib-resistant GIST using network-based methods and validates six drugs that reverse MR activity in preclinical models.

This study identifies RREB1 as a key driver of Group 3 medulloblastoma, showing its role in tumor growth and survival through the c-MET signaling pathway.

The paper identifies master regulator modules in human airway epithelial cells reprogrammed by SARS-CoV-2 and finds 11 drugs that reverse these signatures.

This paper evaluates YF2, a CREBBP/p300 activator, showing it enhances cytotoxicity and immune responses in B-cell lymphoma by restoring acetylation and altering the immune microenvironment.

This paper develops a faster radiation biodosimetry method using G0-PCC with RABiT-II, enabling same-day testing for radiation emergencies.

The paper uses large-scale perturbation profiles to analyze drug mechanisms of action and polypharmacology across multiple tumor subtypes and tissues.

The paper validates an RNA-based platform for predicting drug sensitivity in treatment-resistant cancers using patient-derived xenograft models and multi-protein therapies.

The paper uses phosphoproteomic time-series data and the VESPA algorithm to analyze drug resistance mechanisms in colon cancer cells, revealing adaptive signaling rewiring confirmed by CRISPRko assays.

The paper identifies host cell Master Regulator proteins hijacked by SARS-CoV and identifies drugs that can target these proteins to disrupt viral replication.